eCOA Consortium Announces Next Article in a Series for Applied Clinical Trials C-Path’s eCOA Consortium is pleased to announce that “Administering Complex Cognitive Tests Remotely in The Cognitively-Impair
eCOA Consortium Announces Next Article in a Series for Applied Clinical Trials C-Path’s eCOA Consortium is pleased to announce that “Progressing BYOD Adoption” has been published in Applied Clinical Tria
C-Path Awarded FDA Drug Development Tool Research Grant to Develop a Qualification Plan for the PROMIS® Short Form v2.1—Physical Function-Multiple Sclerosis 15a (PROMIS PFMS—15a) C-Path’s Patient-Reported Outcome (PRO) Consortium announced today it has been awarded a U.S. Food and Drug Administratio
C-Path Awarded FDA Drug Development Tool Research Grant to Develop a Qualification Plan for the Symptoms of Major Depressive Disorder Momentary Assessment (SMDDMA) C-Path’s Patient-Reported Outcome (PRO) Consortium announced that it has been awarded a U.S. Food and Drug Administration (FDA)
Innovative Data and Analytics Platform to Accelerate Drug Development for Rare Diseases Launched by C-Path and NORD through an FDA grant, the goal of the new platform is to accelerate the development of cures by addres
Innovative Use of Healthcare Data, ERN Data Management Strategy Multistakeholder Workshop The presentations of the workshop sessions are now available. In order to download the presentations...
C-Path, CPP Share Manuscript That Redefines Parkinson’s Disease C-Path and its Critical Path for Parkinson’s Consortium are pleased to share a new manuscript that redefines Parkinson’s...
FDA qualification of intracranial adjusted hippocampal volumetric magnetic resonance imaging (ICV-HV vMRI) as a prognostic biomarker for pre-dementia clinical trials for Alzheimer disease therapeutics Conrado, D.J., et al.; “FDA qualification of intracranial adjusted hippocampal volumetric magnetic resonance imaging (ICV-HV vMR
Critical Path Institute Rebrands One of Its First Consortia to Highlight Focus on Alzheimer’s Disease Critical Path for Alzheimer’s Disease (CPAD) consortium’s refined, refocused mission centers on accelerating therapy developme